Loss-of-function mutations or deficient expression of SMARCA4 have been increasingly recognized as a hallmark of a subset of highly aggressive cancers, often with poor prognosis and limited therapeutic responsiveness [2,3]. The gene discussed is SMARCA4; the disease is cancer.